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Background: The relationship between glycemic control and lipid abnormalities with urinary albumin-creatinine
ratio (ACR) in chronic kidney disease (CKD) patients with diabetes mellitus (DM) is unknown. We sought to
investigate the association of dyslipidemia and glycemic control with levels of albuminuria in the National Kidney
Foundation (NKF) Kidney Early Evaluation Program (KEEP) participants with DM and CKD stage 3 or higher.
Methods: We performed a cross-sectional study of 6639 eligible KEEP patients with DM and CKD Stage 3 to 5 from
June 2008 to December 2009. Multivariate logistic regression was used to evaluate the association of lipid
parameters (per 10 mg/dl change in serum level) and glycosylated hemoglobin (HbA1c) values with three degrees
of albuminuria normo (<30 mg⁄g), micro (30 to 300 mg⁄g) and macro (>300 mg⁄g).
Results: 2141 KEEP participants were included. HbA1c levels were strongly associated with micro-albuminuria
(compared to normo-albuminuria) and macro-albuminuria (compared to normo-albuminuria and micro-
albuminuria). Each 1.0% increase in HbA1c increased the odds of micro-albuminuria by 32% (OR 1.32, 95% CI 1.23-
1.42) and the odds of macro-albuminuria (vs. microalbuminuria) by 16% (OR 1.16, 95% CI 1.05-1.28). Only increases
in serum HDL were associated with decreased odds of micro-albuminuria; otherwise, the association between other
components of the serum lipid profile with urinary ACR did not reach statistical significance.
Conclusion: In this cross-sectional study of 2141 KEEP participants with DM and CKD stages 3–5, overall glycemic
control but not lipids were associated with abnormal urinary albumin excretion, a marker of increased risk for
progressive disease.
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Prevalence of chronic kidney disease (CKD) is increasing in
the United States from approximately 12.7% reported in
the National Health and Nutrition Examination Survey
(NHANES) III (1988–1994) to 15.1% reported in the 2009
United States Renal Data System (USRDS) Annual Data
Report, based on NHANES (2003–2006) data. CKD is a
major cause of cardiovascular disease (CVD) morbidity and
mortality worldwide and is now widely recognized as an* Correspondence: drsbose@gmail.com
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reproduction in any medium, provided the orindependent risk for the development of CVD [1]. The re-
lationship between CKD and CVD is complex but appears
to be bidirectional, where therapy directed at improving
natural history of one generally improves prognosis of the
other. Specifically, CVD outcomes have been shown to
improve with the treatment of risk factors commonly found
in association with CKD progression including hyperten-
sion, diabetes mellitus (DM), and dyslipidemia [2].
Increasing albuminuria is a recognized predictor for
CVD. Even mild elevations in the range of micro-
albuminuria (30–299 mg/day) are associated with
atherogenic lipoprotein abnormalities that promoted. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2369/13/104endothelial dysfunction and CVD [3-5]. Serum lipid ab-
normalities have been established as a strong risk factor
for CVD in the general population and are associated
with advanced DM-related CKD and nephrotic range
proteinuria. There is evidence that lipid abnormalities
are associated with urinary albumin excretion (UAE) in
patients with diabetes [6,7]. Increased UAE was found to
be associated with ApoB-containing lipoproteins in
patients with diabetes and the phenotype of hypertrigly-
cerides/hyper-ApoB [6].
Our understanding of the lipid abnormalities asso-
ciated with CKD and proteinuria are limited to cor-
relative studies and targeting reductions in LDL. In
this context, the relationship between dyslipidemia
and diabetic kidney disease is derived from studies on
HMG-coA reductase inhibition reducing proteinuria.
However, limited data suggest that elevations in tri-
glycerides have been implicated as a potential risk
factor for progression of diabetic kidney disease [7].
Even less attention has been paid to the role of low
versus high HDL parameters. We hypothesized that
increasing levels of proteinuria would be associated
with alterations in dyslipidemia and dysglycemia in
patients with DM and CKD. We thus investigated the
relationship between proteinuria, dyslipidemia, and
dysglycemia in participants in the National Kidney




KEEP is a free community-based health-screening pro-
gram that targets populations aged ≥18 years at high risk
of kidney disease, defined as history of diabetes or hyper-
tension or a first order relative with diabetes, hyperten-
sion, or kidney disease, as has been described previously.
Screening methods have been reported previously [8].
Since August 2000, the program has screened ≥128,000
participants from 50 states and the District of Colombia.
The KEEP database has been fully described in previous
reports [9-12]. The Human Subjects Committees at the
University of Minnesota approved this study. All proce-
dures were in accordance with the Helsinki Declaration
of 1975 as revised in 1983 and Title 45, U.S. Code of
Federal Regulations, Part 46, Protection of Human Sub-
jects, Revised November 13, 2001. Prior to enrollment,
participants provided written informed consent. All
authors were granted free access to the database.
This study included a total of 6639 eligible KEEP
patients from June 2008 to December 2009 with HbA1c
values. After excluding non-diabetic patients, non-CKD
patients, and patients with missing values of urinary
albumin-creatinine ratio (ACR), the total sample size
was 2141.Definitions
Estimated glomerular filtration rate GFR (eGFR) was cal-
culated using the 4-variable Modification of Diet in
Renal Disease (MDRD) study equation, and serum cre-
atinine was calibrated by the Cleveland Clinic Research
Laboratory [13]. We would like to re-emphasize that
CKD stage 3 was defined using KDOQI/KDIGO criteria
as an NKF initiative with an estimated GFR <60 ml/min
per 1.73m2 or >60 with an albumin to creatinine ratio
>30mg /g. ACR were calculated from urine samples and
recorded as <30 mg⁄g, 30 to 300 mg⁄g, or >300 mg⁄g.
Microalbuminuria was defined as ACR of 30–300 mg/g,
and macroalbuminuria, as ACR >300 mg/g. CKD was
defined by an eGFR <60 mL⁄min⁄ 1.73 m2 or eGFR >60
with an ACR >30 mg/g. Other definitions included (1)
hypertension: average systolic blood pressure >129 mm
Hg or diastolic blood pressure >84 mm Hg (as per ATP III
criteria for hypertension in association with dyslipidemia,
glucose intolerance and abdominal obesity in metabolic
syndrome) or a self-reported history of hypertension or
patients taking blood pressure–lowering medication; and
(2) dyslipidemia: triglyceride level >150 mg⁄dL or total
cholesterol >200 mg⁄dL; (3) Diabetes mellitus: self-
reported diabetes mellitus, retinopathy, and taking diabetic
medications (including insulin). Other measures, including
education level, tobacco and alcohol uses, and family his-
tory of diseases, were self-reported. Blood pressure, height,
weight, and waist circumference were directly measured
for all participants.
Statistical Analysis
Demographic and baseline characteristics of the study
population based on quartiles of glycosylated
hemoglobin (HbA1c) were compared. Values were
expressed as frequency (percent) unless noted otherwise.
KEEP health screening results for the participants were
also categorized by HbA1c values. We performed multi-
variate logistic regression analyses to evaluate individual
association of lipid parameters (per 10 mg/dl change in
serum level) and HbA1c values with ACR, adjusting for
risk factors such as age, gender, race, status of hyperten-
sion and smoking. These associations were compared
across different degrees of ACR: normo-albuminuria
(<30 mg⁄g), micro-albuminuria (30 to 300 mg⁄g) and
macro-albuminura (>300 mg⁄g).
Results
The final eligible sample size included 2141 KEEP parti-
cipants with diabetes and CKD stage 3–5 (Table 1). Par-
ticipants were grouped into 4 quartiles of glycemic
control delineated by HbA1c values: ≤6.2%, 6.3-6.9%,
7.0-8.1%, and ≥8.2%. The participants were predomin-
antly female (65%) and non-hispanic white (57.5%) with
a median age of 66 years (range 58–75). Participants
Table 1 Clinical Characteristics of KEEP Participants, 2008–2009, by Level of Glycemic Control as Evident by HbA1c




All, n Q1 Q2 Q3 Q4
[4.5 to 6.2] [6.3 to 6.9] [7.0 to 8.1] [8.2 to 18.0]
n (row percentage) 2141 (100) 576 (26.9) 564 (26.3) 482 (22.5) 519 (24.2)
Age † 66 (58–75) 69 (61–77) 72 (63–78) 67 (60–75) 59 (50–68) <.0001
Sex 0.2123
Men 749 (35) 188 (32.6) 183 (32.5) 190 (39.4) 188 (36.2)
Women 1392 (65) 388 (67.4) 381 (67.5) 292 (60.6) 331 (63.8)
Race <.0001
NHW 1233 (57.5) 382 (66.3) 354 (62.8) 291 (60.4) 206 (39.7)
NHAA 511 (24) 120 (20.8) 129 (22.9) 113 (23.4) 149 (28.7)
Hispanic 215 (10) 43 (7.5) 49 (8.7) 38 (7.9) 85 (16.4)
Other race 182 (8.5) 31 (5.4) 32 (5.7) 40 (8.3) 79 (15.2)
≥ High school education 1740 (81.2) 477 (83.5) 467 (83.8) 390 (82.1) 406 (79.0) 0.0546
Current smoker 144 (6.7) 43 (7.6) 29 (5.3) 22 (4.6) 50 (10.0) 0.1773
Hypertensive 1991 (93) 535 (92.9) 525 (93.1) 445 (92.3) 486 (93.6) 0.6171
Family history of kidney disease 301 (14.4) 81 (14.4) 72 (13.1) 70 (15.0) 78 (15.2) 0.7562
Urinary ACR≥30 mg/g 1093 (51) 234 (40.6) 235 (41.7) 236 (49.0) 388 (74.8) <.0001
Note: Values are n (column percent) unless otherwise indicated.
Abbreviations: HbA1c, Glycosylated Hemoglobin; KEEP, Kidney Early Evaluation Program; NHW, Non-Hispanic White; NHAA, Non-Hispanic African American; ACR,
Albumin-creatinine ratio.
† Median (IQR).
} chi2 for categorical variables and t-test for continuous variables.
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younger than participants with the best glycemic control.
African-American and Hispanic participants were sig-
nificantly over-represented in the highest quartile of
HbA1c values. There was a high prevalence of concomi-
tant hypertension (93%) in this cohort, yet only 144 par-
ticipants (6.7%) self-reported current cigarette smoking.
Mean serum creatinine and estimated GFR for the co-
hort were 1.2 mg/dl and 59.2 ml/min/1.73 m2, respect-
ively. Roughly half (51%) of the participants had
abnormal UAE, defined as ACR≥ 30 mg/g. This preva-
lence rose significantly across quartiles of HbA1c, with
participants in the highest quartile (A1c ≥8.2%) having
nearly double the prevalence of abnormal ACR as parti-
cipants in the lower quartile (A1c ≤ 6.2%). In Table 1, we
have presented the statistical comparison between the
groups of KEEP participants with the lowest (Q1) and
highest (Q4) quartiles of HbA1c. We have also provided
the statistical comparison of clinical characteristics
across all HbA1c quartiles in Additional file 1: Table S1.
Health screening results categorized by overall gly-
cemic control (HbA1c quartiles) of individual partici-
pants varied significantly (Table 2). When compared
across different quartiles of HbA1c values (Additional
file 2: Table S2), a number of measures of metabolic
derangements, including measures of anthropometry
(body mass index - BMI and waist circumference),serum total cholesterol, low-density lipid (LDL), trigly-
ceride (TG), and elevated urinary ACR values had incre-
mental increases with rising HbA1c. Although serum
Low-density lipid (LDL) were within normal range
tended to increase with HbA1c except in quartile 1.
High-density lipid (HDL) values, as expected, decreased
across increasing quartiles of HbA1c.
In multivariate regression analyses (Table 3) control-
ling for age, gender, race, presence of hypertension and
tobacco sue, only increased HDL was associated with a
small, but significant, decreased odds of micro-
albuminuria (vs. normo-albuminuria). Otherwise, across
the range of micro- and macro-albuminuria assayed in
the KEEP screenings, no lipid component was associated
with ACR. Conversely, increased HbA1c was consist-
ently and strongly correlated with level of albuminuria,
whether the comparison was made between micro- and
normo-albuminuria (OR 1.32, 95% CI 1.23-1.42), macro-
albuminuria and non macro-albuminuria (OR 1.26, 95%
CI 1.14-1.38), or macro-albuminuria vs. micro-
albuminuria (OR 1.16, 95% CI 1.05-1.28).
Discussion
In this cross-sectional analysis of over 2000 KEEP partici-
pants with DM and CKD stages 3–5, we report that poor
glycemic control is associated with micro-albuminuria and
macro-albuminuria. These same associations were not
Table 2 Health screening results categorized by HbA1c: KEEP database (2008–2009)




All, n Q1 Q2 Q3 Q4
[4.5 to 6.2] [6.3 to 6.9] [7.0 to 8.1] [8.2 to 18.0]
n (row percentage) 2141 (100) 576 (26.9) 564 (26.3) 482 (22.5) 519 (24.2)
SBP (mm of Hg) { 138 (124–150) 136 (123–149) 137 (123–151) 138 (124–149) 139 (128–151) 0.0942
DBP (mm of Hg) { 78 (70–86) 78 (70–85) 75 (68–84) 78 (70–86) 80 (72–89) 0.0001
PP (mm of Hg) { 59 (48–70) 58 (48–70) 60 (48.5-71) 60 (49–70) 58 (49–69) 0.3544
BMI (kg/m2){ 31.2 (27.4-36.6) 29.8 (26.3-34.9) 31.1 (27.3-36.3) 31.6 (27.7-36.8) 33.2 (28.7-38.3) <.0001
WC (cm){ 42 (38–46) 41 (37–45) 42 (38–46) 42 (39–47) 44 (39–48) <.0001
Serum creatinine 1.13 (0.95-1.34) 1.15 (0.99-1.37) 1.16 (0.99-1.37) 1.17 (0.96-1.36) 1.03 (0.85-1.28) <.0001
Estimated GFR 55.4 (46.1-68.9) 54.4 (44.7-59.8) 53.0 (44.6-59.5) 54.8 (45.9-65.3) 63.0 (50.4-84.4) <.0001
Serum TC (mg/dl) { 177 (150–207) 178.5 (151.5-201.5) 170.0 (146.5-199.0) 171.0 (146.0-203.0) 188.0 (159.0-226.0) <.0001
Serum LDL (mg/dl) { 89.5 (67–114) 90.5 (69–113) 84 (64–109) 86 (66–110) 98 (73–128) 0.0002
Serum HDL (mg/dl) { 47 (38–57) 50 (41–61.5) 48 (39–57) 45 (38–54) 44 (37–55) <.0001
Serum TG (mg/dl) { 170 (117–250) 150 (108.5-214.5) 164.5 (113–241) 169 (114–253) 201 (142–301) <.0001
Urinary ACR (mg/g) <.0001
< 30 1048 (49.0) 342 (59.4) 329 (58.3) 246 (51.0) 131 (25.2)
30 -300 966 (45.1) 210 (36.5) 214 (37.9) 205 (42.5) 337 (64.9)
> 300 127 (5.9) 24 (4.2) 21 (3.7) 31 (6.4) 51 (9.8)
Serum Calcium (mg/dl) { 9.7 (9.4-10) 9.7 (9.4-10.0) 9.7 (9.4-10.0) 9.6 (9.3-9.9) 9.6 (9.3-9.9) 0.4078
Serum Phosphorus (mg/dl){ 3.6 (3.2-4) 3.6 (3.2-4.0) 3.6 (3.2-4.0) 3.6 (3.2-3.9) 3.65 (3.2-4.0) 0.4301
Hemoglobin (g/dl) { 13.3 (12.2-14.3) 13.2 (12.1-14.3) 13.1 (12.1-14.0) 13.3 (12.2-14.4) 13.7 (12.4-14.7) <.0001
Note: Values are n (column percent) unless otherwise indicated.
Abbreviations: HbA1c, Glycosylated Hemoglobin; KEEP, Kidney Early Evaluation Program; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; PP, Pulse
Pressure; BMI, Body Mass Index; WC, Waist Circumference; TC, Total Cholesterol; LDL, Low Density Lipoprotein; HDL, High Density Lipoprotein; TG, Triglyceride; ACR,
Albumin-creatinine ratio.
{ Median (IQR).
} chi2 for categorical variables and t-test for continuous variables.
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present. Given that abnormal UAE is felt to be a marker of
significantly high-risk kidney disease for any level of GFR,
including a much greater risk for both rapid progression
to end stage renal disease and premature cardiovascular
morbidity and mortality, these data corroborate focusing
on glycemic control in CKD patients with diabetes.
Several reports have identified the presence of CKD in
DM patients with normoalbuminuria [14,15], but devel-
opment of microalbuminuria has been considered to be
one of the first detectable signs of the classic course of
diabetic nephropathy that leads to CKD and, eventually,
CVD and end-stage renal disease (ESRD). Consequently,
there is a pressing need to further explore the role of
risk factors for abnormal urinary albumin excretion,
which conceivably “gets the ball rolling” in the patho-
genesis of diabetic kidney disease. Glycemic control and
dyslipidemia are two leading candidates for such risk
factors.
Glycemic control, as evidenced by HbA1c, has previ-
ously been shown to be an independent risk factor for
the development of microalbuminuria in type 1 and 2diabetes mellitus in prospective study of normoalbumi-
nuric patients [16]. However, our understanding of the
relationship between proteinuria and glycemic control is
largely derived from investigations targeting glycemic
reductions and using proteinuria as a measure of kidney
function in populations with preserved or only mildly
impaired renal function. Several large randomized con-
trolled trials, including the Diabetes Control and Com-
plications Trial in type 1 diabetes [17], the UK
Prospective Diabetes Study [18], and the Kumamoto
Study [19], indicate that tighter glycemic control can de-
crease the risk of nephropathy. Recently, the ADVANCE
trial [20] documented in subjects with DM that strict
glycemic control (mean HbA1c: 6.5%), in comparison
with the standard control (mean HbA1c: 7.3%), is asso-
ciated with a significant reduction in renal events, in-
cluding onset of or worsening of nephropathy [hazard
ratio (HR) 0.79; p= 0.006], new-onset microalbuminuria
(HR 0.91; p= 0.02) and, in particular, development of
macroalbuminuria (HR 0.70; p < 0.001).
However, information about the effect of strict gly-
cemic control on outcome in diabetic patients with
Table 3 Association of albuminuria with components of
serum lipid panel and HbA1c
Adjusted for age, gender, race,
hypertension, and current smoker
Odds ratio (95% Confidence
Interval)
(A) Micro-albuminuria Vs normo-albuminuria group:
Total Cholesterol (mg/dl) (per 10) 1.03 (0.94-1.13)
Serum LDL (mg/dl) (per 10) 1.00 (0.91-1.10)
Serum HDL (mg/dl) (per 10) 0.88 (0.78-0.99)*
Serum Triglyceride (mg/dl) (per 10) 0.99 (0.97-1.01)
HbA1c 1.32 (1.23-1.42)***
(B) Macro-albuminuria Vs Non macro-albuminuria (Normo + Micro) group:
Total Cholesterol (mg/dl) (per 10) 0.89(0.71-1.10)
Serum LDL (mg/dl) (per 10) 1.13 (0.90-1.42)
Serum HDL (mg/dl) (per 10) 1.20 (0.94-1.53)
Serum Triglyceride (mg/dl) (per 10) 1.01 (0.98-1.04)
HbA1c 1.26 (1.14-1.38)***
(C) Macro-albuminuria Vs micro-albuminuria group:
Total Cholesterol (mg/dl) (per 10) 0.90(0.73-1.11)
Serum LDL (mg/dl) (per 10) 1.11 (0.89-1.37)
Serum HDL (mg/dl) (per 10) 1.25 (0.98-1.59)
Serum Triglyceride (mg/dl) (per 10) 1.01 (0.98-1.05)
HbA1c 1.16 (1.05-1.28)**
* p < 0.05, **p < 0.01, ***p < 0.001.
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http://www.biomedcentral.com/1471-2369/13/104established CKD is very limited [21], making it difficult
to extrapolate that these positive effects of intensive gly-
cemic control are indeed present in DM patients with
moderate to advanced CKD. Therefore, our finding that
poor overall glycemic control as evident from HbA1c
values is significantly associated with proteinuria
strengthens our understanding of the relationship be-
tween diverse metabolic risks and CKD progression.
This relationship remained significant even after adjust-
ing for co-variables (e.g. hypertension, smoking status)
that are known to influence albuminuria. The strength
of association of HbA1c with ACR was reduced when
compared between micro-albuminuria and macro-
albuminuria groups in our study. This finding could be
reflection of the fact that HbA1c levels might underesti-
mate mean blood glucose levels in patients with CKD
and especially in diabetic subjects with severe nephropa-
thy as evident from macro-albuminuria [22,23].
Dyslipidemia has been shown to be independently
associated with micro [24] and macrovascular [25] dis-
eases. A link between dyslipidemia and nephropathy has
been demonstrated by prospective studies in the past
[26,27]. However, understanding lipid fractions mea-
sured in these studies were limited due to the lack of in-
formation obtained regarding lipid-lowering therapies as
well as fasting status and the lack of association with
kidney disease is likely driven by the relatively normalmeasures. However, the importance of lipid abnormal-
ities in kidney disease can not be understated. Other
studies on patients with type 1 diabetes suggest a differ-
ential association between lipid variables and kidney dis-
ease depending upon the duration of diabetes [28] or the
stage of renal impairment [29]. More recently, serum
Apo(B) and Lp(a) increases have been reported at the
stages of microalbuminuria and macroalbuminuria, re-
spectively, in a cohort of type 2 diabetic patients but tri-
glyceridemia was significant throughout the three stages
of albuminuria [30]. In addition, decreased eGFR has
been shown to be independently associated with greater
odds of having a low HDL level [31]. Despite all these
statistical associations between dyslipidemia and albu-
minuria, it is uncertain whether impaired lipid metabol-
ism in CKD patients contributes to the progression of
kidney disease [32] or, instead, progression of CKD and
onset of significant albuminuria itself causes dyslipide-
mia [33].
In our study, neither microalbuminuria, nor macroal-
buminuria was associated with lipids in screened KEEP
participants. This finding partly may be explained by
only 6% of the study population having overt protein-
uria. Our understanding of dyslipidemia in CKD is in
more advanced stages of CKD (i.e. stages 4–5) or with
more significant proteinuria. Interestingly, we also found
that HDL is negatively associated with ACR when com-
pared between normo-albuminuria and micro-albumin-
uria. This association was not sustained when compared
between micro-albuminuria and macro-albuminuria
groups, perhaps underscoring other metabolic adverse
effects that may contribute to low HDL in patients with
advanced CKD or macroalbuminuria [31].
Our study does have several limitations that should be
noted. The cross-sectional nature prohibits inference on
causation. Secondly, we rely on single measurements of all
laboratory parameters as screening program. While
HbA1c values should not significantly change on repeated
measurements (assuming glycemic control remains con-
stant), conceivably both urinary ACR values and, more no-
ticeably, lipid measurements can be affected by time of
testing and pre-testing diet (e.g. fasting status). In addition,
HbA1c values may underestimate mean blood glucose
levels in CKD patients, particularly those with CKD-
associated anemia, although this should be a non-
directional bias towards the null in this cohort in which all
participants had CKD. Finally, we do not have medication
data on these participants including lipid-lowering therap-
ies, which may influence the interpretation of the pre-
sented data. For example, if we knew that all patients in
this cohort were on cholesterol-lowering medications such
as statins, then we could theoretically explain the lack of
association between rising lipid abnormalities and urinary
ACR by a protective effect of statins.
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In conclusion, our findings demonstrate a strong correl-
ation of overall glycemic control and abnormal urinary
albumin excretion in patients with CKD and DM. Ab-
sence of similar association with dyslipidemia under-
scores the paramount importance of sustained blood
glucose control in this population at high risk for cardio-
vascular disease and end stage renal disease. Until fur-
ther prospective studies clearly delineate a causal link
between lipid abnormalities and outcomes, it appears
prudent for practitioners to continue to address lipid ab-
normalities in this population but to keep sustained em-
phasis on glycemic control, too.
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